• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病患者药物治疗不依从的成本:文献的系统评价与批判性分析

Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature.

作者信息

Salas Maribel, Hughes Dyfrig, Zuluaga Alvaro, Vardeva Kawitha, Lebmeier Maximilian

机构信息

Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL 35294-4410, USA.

出版信息

Value Health. 2009 Sep;12(6):915-22. doi: 10.1111/j.1524-4733.2009.00539.x. Epub 2009 Apr 27.

DOI:10.1111/j.1524-4733.2009.00539.x
PMID:19402848
Abstract

OBJECTIVES

Information on the health care costs associated with nonadherence to treatments for diabetes is both limited and inconsistent. We reviewed and critically appraised the literature to identify the main methodological issues that might explain differences among reports in the relationship of nonadherence and costs in patients with diabetes.

METHODS

Two investigators reviewed Medline, EMBASE, Cochrane library and CINAHL and studies with information on costs by level of adherence in patients with diabetes published between January 1, 1997 and September 30th 2007 were included.

RESULTS

A total of 209 studies were identified and ten fulfilled the inclusion criteria. All included studies analyzed claims data and 70% were based on non-Medicaid and non-Medicare databases. Low medication possession ratios were associated with higher costs. Important differences were found in the ICD-9/ICD-9 CM codes used to identify patients and their diagnoses, data sources, analytic window period, definitions of adherence measures, skewness in cost data and associated statistical issues, adjustment of costs for inflation, adjustment for confounders, clinical outcomes and costs.

CONCLUSIONS

Important variation among cost estimates was evident, even within studies of the same population. Readers should be cautious when comparing estimated coefficients from various studies because methodological issues might explain differences in the results of costs of nonadherence in diabetes. This is particularly important when estimates are used as inputs to pharmacoeconomic models.

摘要

目的

关于糖尿病治疗不依从相关医疗保健成本的信息有限且不一致。我们回顾并批判性地评估了文献,以确定可能解释糖尿病患者不依从与成本关系报告差异的主要方法学问题。

方法

两名研究人员检索了Medline、EMBASE、Cochrane图书馆和CINAHL,并纳入了1997年1月1日至2007年9月30日期间发表的有关糖尿病患者依从性水平与成本信息的研究。

结果

共识别出209项研究,其中10项符合纳入标准。所有纳入研究均分析了理赔数据,70%基于非医疗补助和非医疗保险数据库。低药物持有率与更高成本相关。在用于识别患者及其诊断的ICD - 9/ICD - 9 CM编码、数据来源、分析窗口期、依从性测量定义、成本数据的偏态及相关统计问题、成本的通胀调整、混杂因素调整、临床结局和成本方面发现了重要差异。

结论

即使在同一人群的研究中,成本估计之间也存在明显差异。在比较不同研究的估计系数时,读者应谨慎,因为方法学问题可能解释糖尿病不依从成本结果的差异。当估计值用作药物经济学模型的输入时,这一点尤为重要。

相似文献

1
Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature.糖尿病患者药物治疗不依从的成本:文献的系统评价与批判性分析
Value Health. 2009 Sep;12(6):915-22. doi: 10.1111/j.1524-4733.2009.00539.x. Epub 2009 Apr 27.
2
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
3
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
4
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
5
The measurement and monitoring of surgical adverse events.手术不良事件的测量与监测
Health Technol Assess. 2001;5(22):1-194. doi: 10.3310/hta5220.
6
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
7
Eliciting adverse effects data from participants in clinical trials.从临床试验参与者中获取不良反应数据。
Cochrane Database Syst Rev. 2018 Jan 16;1(1):MR000039. doi: 10.1002/14651858.MR000039.pub2.
8
Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.吸入装置在哮喘和慢性阻塞性气道疾病中的有效性比较:文献系统评价
Health Technol Assess. 2001;5(26):1-149. doi: 10.3310/hta5260.
9
Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.吡格列酮和罗格列酮治疗2型糖尿病的临床疗效和成本效益:系统评价与经济评估
Health Technol Assess. 2004 Apr;8(13):iii, ix-x, 1-91. doi: 10.3310/hta8130.
10
Comparison of cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease.纤维素、改性纤维素和合成膜在终末期肾病患者血液透析中的比较。
Cochrane Database Syst Rev. 2001(3):CD003234. doi: 10.1002/14651858.CD003234.

引用本文的文献

1
Pharmacoeconomic Aspects of Diabetes Mellitus: Outcomes and Analysis of Health Benefits Approach.糖尿病的药物经济学方面:健康效益方法的结果与分析
Curr Diabetes Rev. 2024;20(8):12-22. doi: 10.2174/0115733998246567230924134603.
2
Implementing a text message-based intervention to support type 2 diabetes medication adherence in primary care: a qualitative study with general practice staff.在基层医疗中实施基于短信的干预措施以支持 2 型糖尿病药物治疗依从性:一项针对全科医疗工作人员的定性研究。
BMC Health Serv Res. 2023 Jun 10;23(1):614. doi: 10.1186/s12913-023-09571-9.
3
Medication Adherence and Healthcare Costs in Chronically Ill Patients Using German Claims Data.
利用德国索赔数据研究慢性病患者的药物依从性和医疗保健费用。
Appl Health Econ Health Policy. 2023 May;21(3):477-487. doi: 10.1007/s40258-023-00797-6. Epub 2023 Mar 18.
4
Supporting People With Type 2 Diabetes in the Effective Use of Their Medicine Through Mobile Health Technology Integrated With Clinical Care to Reduce Cardiovascular Risk: Protocol for an Effectiveness and Cost-effectiveness Randomized Controlled Trial.通过与临床护理相结合的移动健康技术支持2型糖尿病患者有效用药以降低心血管风险:一项有效性和成本效益随机对照试验方案
JMIR Res Protoc. 2022 Feb 21;11(2):e32918. doi: 10.2196/32918.
5
Differential Cost-Sharing Undermines Treatment Adherence to Combination Therapy: Evidence from Diabetes Treatment.差别成本分担会削弱对联合治疗的治疗依从性:来自糖尿病治疗的证据。
Diabetes Ther. 2021 Aug;12(8):2149-2164. doi: 10.1007/s13300-021-01098-8. Epub 2021 Jul 1.
6
System Architecture for "Support Through Mobile Messaging and Digital Health Technology for Diabetes" (SuMMiT-D): Design and Performance in Pilot and Randomized Controlled Feasibility Studies.“通过移动消息和数字健康技术支持糖尿病患者”(SuMMiT-D)系统架构:试点研究和随机对照可行性研究中的设计与性能
JMIR Form Res. 2021 Mar 26;5(3):e18460. doi: 10.2196/18460.
7
Efficacy, safety and cost-effectiveness comparison between U-100 human regular insulin and rapid acting insulin when delivered by V-Go wearable insulin delivery device in type 2 diabetes.U-100人常规胰岛素与速效胰岛素经V-Go可穿戴胰岛素输送装置用于2型糖尿病治疗时的疗效、安全性及成本效益比较
BMJ Open Diabetes Res Care. 2020 Nov;8(2). doi: 10.1136/bmjdrc-2020-001832.
8
Treatment Patterns, Adherence, and Persistence Associated With Human Regular U-500 Insulin: A Real-World Evidence Study.与人类常规U-500胰岛素相关的治疗模式、依从性和持续性:一项真实世界证据研究。
Diabetes Spectr. 2020 Aug;33(3):264-272. doi: 10.2337/ds19-0060.
9
Supporting people with type 2 diabetes in effective use of their medicine through mobile health technology integrated with clinical care (SuMMiT-D Feasibility): a randomised feasibility trial protocol.通过与临床护理相结合的移动健康技术支持2型糖尿病患者有效用药(SuMMiT-D可行性研究):一项随机可行性试验方案
BMJ Open. 2019 Dec 29;9(12):e033504. doi: 10.1136/bmjopen-2019-033504.
10
Opportunities for improving use of evidence-based therapy in patients with type 2 diabetes and cardiovascular disease.改善 2 型糖尿病和心血管疾病患者循证治疗应用的机会。
Clin Cardiol. 2019 Nov;42(11):1063-1070. doi: 10.1002/clc.23252. Epub 2019 Aug 26.